Dipal Doshi

Dipal Doshi

DirectoratEntrada Therapeutics· In proxies 2023–2025

Pay in FY2024+4% from the year before · Entrada Therapeutics stock +14.6% the same year

Dipal Doshi was paid $3.9M in FY2024 (Dec), up 4%. Entrada Therapeutics stock rose 14.6% that year.

Pay$100 in the stock at the end of FY22 → $128
Pay is from the Summary Compensation Table of each Entrada Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. AzentaPublic company · 2 yr
    • Director2024 – Present · 2 yrNo stock prices for these years
  2. Entrada TherapeuticsPublic company · 3 yr
    • Chief Executive Officer2023 – Present · 3 yrStock in role -68%
  3. AuditPublic company
    • Director? – PresentNo stock prices for these years
  4. Entrada Therapeutics (NASDAQ: TRDA)Public company
    • Director? – PresentNo stock prices for these years

Roles come from the proxy statements of each company.

Activity

No new filings about this person in the feed.

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?